Radius Health (RDUS) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Radius Health Reports Third Quarter 2017 Financial and Operating Results and Provides Business Update
November 2, 2017 4:02 PM EDTFirst full quarter of TYMLOS sales shows accelerating market share & stabilization of the anabolic market
Plan access at approximately 200 million lives 87% commercial and 35% Medicare
Male Osteo Trial: FDA agreÂement on the design of a clinical trial in men
FDA Fast Track Designation for elacestrant (RAD1901)
First patient enrolled in Phase 1 study of RAD140
Strengthened balance sheet with $305 million convertible debt offering
WALTHAM, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the... More
